Safety of talimogene laherparepvec: a real‐world retrospective pharmacovigilance study based on FDA Adverse Event Reporting System (FAERS)
Most AEs in T-VEC-treated patients have been previously mentioned in the prescriptive information or documented in other clinical trials. But safety signals were also be detected in 4 unexpected AEs (sepsis, encephalitis, syncope, and lymphadenopathy). Further clinical trials need to be undertaken to facilitate a more comprehensive comprehension of the safety profile of T-VEC.
Authors
- Han Qu (ORCID: https://orcid.org/0000-0001-9701-4748)
- Zhenghua Wu (ORCID: https://orcid.org/0000-0001-8639-9689)
- Guorong Fan (ORCID: https://orcid.org/0000-0002-4417-7225)
- Yuting Wang (ORCID: https://orcid.org/0000-0003-3990-2418)
- Yifan Hong (ORCID: https://orcid.org/0009-0007-6079-5895)
- Kebin Cheng (ORCID: https://orcid.org/0000-0002-2617-9702)
- Yuanyuan Wang (ORCID: https://orcid.org/0000-0002-5576-6375)
Institutions
- Tongji University (CN)
- Shanghai Jiao Tong University (CN)
- Shanghai Changzheng Hospital (CN)
- Shanghai Pulmonary Hospital (CN)
- Shanghai First People's Hospital (CN)
Publication Details
- Journal
- Journal of Pharmaceutical Health Care and Sciences
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1186/s40780-024-00388-0
- Citations
- 3
- Primary Topic
- Virus-based gene therapy research
- Type
- article
- Field-Weighted Citation Impact
- 1.65
Funders
- Wu Jieping Medical Foundation